{
    "clinical_study": {
        "@rank": "148067", 
        "arm_group": {
            "arm_group_label": "Diagnostic (bioelectric impedance analysis)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies bioelectrical impedance phase angle in predicting treatment\n      outcome in patients with extensive stage small cell lung cancer receiving first-line\n      chemotherapy. Diagnostic procedures, such as bioelectrical impedance analysis, may help\n      predict a patient's response to treatment for small cell lung cancer."
        }, 
        "brief_title": "Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy", 
        "condition": "Extensive Stage Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the association between phase angle (PA) measurement and progression-free\n      survival (PFS).\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the association between PA measurement and treatment-related outcomes of\n      treatment response, adverse treatment events, and overall survival (OS).\n\n      II. To determine the feasibility of obtaining PA measurements at a single time point in\n      patients undergoing evaluation in thoracic oncology clinics.\n\n      OUTLINE:\n\n      Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.\n\n      After completion of study treatment, patients are followed up every 2-3 months for two\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A primary histopathological and/or cytopathological diagnosis of small cell lung\n             cancer (SCLC)\n\n          -  Diagnosis of extensive stage disease (extensive stage [ES]-SCLC), with stage\n             established by computed tomography (CT), magnetic resonance imaging (MRI), or\n             positron emission tomography (PET) scan\n\n          -  Scheduled to receive front-line platinum-based chemotherapy with carboplatin or\n             cisplatin plus etoposide\n\n          -  Ability to understand and the willingness to sign an institutional review board\n             (IRB)-approved informed consent document\n\n        Exclusion Criteria:\n\n          -  No recent chemotherapy or surgery, as defined as in the last 6 months\n\n          -  Presence of a pacemaker or defibrillator\n\n          -  Patients with major chronic disease known to adversely affect PA, including human\n             immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive\n             heart failure, tuberculosis\n\n          -  Patients with body mass index (BMI) greater than 34 or less than 16\n\n          -  Any condition or abnormality which may, in the opinion of the investigator,\n             compromise the safety of patients\n\n          -  Unable or unwilling to follow protocol requirements\n\n          -  Pregnant women are excluded from participation due to inability to participate in\n             required chemotherapy regimen"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011087", 
            "org_study_id": "CCCWFU 99813A", 
            "secondary_id": [
                "NCI-2013-02339", 
                "CCCWFU 99813A", 
                "P30CA012197"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Diagnostic (bioelectric impedance analysis)", 
            "description": "Undergo bioelectric impedance analysis", 
            "intervention_name": "bioelectric impedance analysis", 
            "intervention_type": "Procedure", 
            "other_name": [
                "BIA", 
                "bioelectric impedance", 
                "bioelectric impedance test", 
                "bioimpedance analysis"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "contact": {
                "email": "jruiz@wakehealth.edu", 
                "last_name": "Jimmy Ruiz", 
                "phone": "336-716-4464"
            }, 
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Comprehensive Cancer Center of Wake Forest University"
            }, 
            "investigator": {
                "last_name": "Jimmy Ruiz", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Small Cell Lung Cancer", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "Jimmy Ruiz", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Analyzed using Kaplan-Meier plots and a log-rank test to test the difference in progression-free survival and high/low phase angle measures.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "From the start of treatment to the time of progression, death, or date of last contact, assessed up to 2 years"
            }, 
            {
                "description": "A Cox proportional hazards model will be used. The standardized phase angle measure will be treated as a continuous measure and baseline characteristics will be included as covariates in the survival model.", 
                "measure": "Standardized phase angle measure", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Logistic regression will be used to analyze the association between standardized phase angle and best overall response.", 
                "measure": "Best overall response (complete, partial, progressive disease, stable disease) using the Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "A Cox proportional hazards model will be used.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From the start of treatment to date of death or date of last contact, assessed up to 2 years"
            }, 
            {
                "description": "For those events that are the most common, the mean standardized phase angle for those experiencing the condition will be presented.", 
                "measure": "Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}